1、novotech-16 September 2024Cervical Cancer-Global Clinical Trial Landscape (2024)The content of this publication is proprietary to Novotech Health Holdings.No part of this publication may be reproduced,distributed,or transmitted in any form or by any means,including photocopying,recording,or other el

2、ectronic or mechanical methods,without the prior written permission of Novotech except in the case of quotations embodied in reviews and non-commercial uses.Please note that this copyright statement applies specifically to this publication and its content and does not extend to other materials or in

3、tellectual property owned by Novotech.Any unauthorized reproduction or distribution of this publication or any portion thereof may result in legal action taken by Novotech to protect its rights.For permissions or inquiries,please contact:communicationsnovotech-#DYK Did youknow?Countries like Mainlan

4、d China,United States,Spain,Australia,and South Korea emerged as top locations for conducting trialsAsia-Pacific showed faster recruitment durationsCERVICAL CANCERTRIAL CONTRIBUTIONSThe CC treatment market ofers diverse products by companies including Akeso Inc.,Amgen Inc.,Baxter International Inc.,

5、and Merck&Co.Inc.Multiple ongoing Phase III trials demonstrate continued eforts to enhance CC treatment through cellular vaccines,antibody,and small moleculesCERVICAL CANCER(CC)GLOBAL CLINICAL TRIAL LANDSCAPE(2024)CERVICALCANCER8thMOSTDIAGNOSEDCANCER9thLEADING CAUSE OF CANCER MORTALITY6%ROW46%NORTH

6、AMERICA&EUROPE48%ASIA-PACIFIC2022:NEARLYNEW CASES 662kAsia had the highest incidence cases and accounted for nearly 60%of the global incidence cases of CCAfrica had the second highest incidence,with over 125,700 casesLatin America and the Caribbean had more than 63,100 cases,followed by Europe and N